

Amyloid imaging for phenotyping lewy body dementia

<https://neurodegenerationresearch.eu/cohort/amyloid-imaging-for-phenotyping-lewy-body-dementia/>

Cohort Acronym

AMPLE

Cohort type

Rare neurodegenerative condition

Disease

Alzheimer's disease, Lewy body disease

Participant type

Condition diagnosed

Profile

Recruitment Period 2013

Sample size at start or planned sample size if still recruiting

Estimated Current Sample Size

Age at Recruitment >60

Gender Male and Female

Abstract

The AMPLE study has been set up to investigate differences and outcomes in those with Lewy body dementia with and without concurrent Alzheimer's disease/pathology. The principle aim of AMPLE is to undertake amyloid PET imaging in Lewy Body Dementia (LBD) and Alzheimer's disease (AD) of 80 participants over the age of 60 and investigate the distribution of amyloid burden in LBD relative to AD and controls at baseline. A further aim is to determine the relationship between amyloid levels at baseline, clinical features of the disease, other imaging changes and subsequent clinical course in follow up.

Primary analysis would divide LBD patients into high and low amyloid burden with participants then compared on clinical features with AD-like symptoms and cognitive profiles. Follow up will be completed annually through surveys and clinical examinations.

Last update – 01/02/2017

Country United Kingdom

Contact details

Institution name Newcastle University

Website <http://www.ncl.ac.uk/car/research/project/5055>

Principal Investigator (PI) Professor John O'Brien

Contact email n.a.barnett@newcastle.ac.uk; M.J.Firbank@ncl.ac.uk

Contact phone number +44 (0) 191 208 1322

Funders (Core support) NIHR Newcastle Biomedical Research Unit|Avid

Variables Collected

Brain related measures:

Behaviour, Cognitive function, Mental health

Functional rating:

Individual physiological, Individual psychological

Anthropometric:

N/A

Physical:

Cardiovascular, Hearing and Vision

Biological samples:

Blood, Cerebral spinal fluid (CSF)

Genotyping:

Gene screening

Brain imaging:

Magnetic resonance imaging (MRI), Positron emission tomography (PET) fluorine18 flurodeoxyglucose (FDG)

Brain banking:

N/A

Lifestyle:

Alcohol, Smoking

Socio-economic:

Education

Health service utilisation:

N/A